CD274 and non-small cell lung carcinoma: Cytotoxic therapies, such as platinum-based chemotherapy, in combination with immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 axis have been shown to profoundly improve efficacies of NSCLC treatment by synergizing to enhance anti-cancer immunity (2–4).